Company Overview and News
AEMULUS Holdings Bhd has seen brief periods of upwards momentum since coming off its historical peak of 75 sen on Aug 1 this year.
Robust demand: VS Industry’s growth has been supported by strong quarterly earnings and mergers and acquisitions throughout the year.
MarketWatch: US stocks sold off on Thursday, with the S&P 500 recording its biggest daily percentage drop in three months as escalating worries about the Trump administration's ability to push through its economic agenda rattled investors. The DJIA ended down 274.14 points, or 1.24%, to 21,750.73, the S&P 500 lost 38.1 points, or 1.54%, to 2,430.01 and the Nasdaq dropped 123.20 points, or 1.94%, to 6,221.
KUALA LUMPUR (Jan 23): Based on corporate announcements and newsflow today, companies that may be in focus tomorrow (Jan 24) could include: LKL, Greenyield, MKH, Iris, Aemulus, EcoWorld, Ni Hsin, DiGi, NWP, Ecofirst and TMC Life Sciences.
KUALA LUMPUR (Aug 15): Aemulus Holdings Bhd shares fell 4.69% in early trade today after CIMB IB Research downgraded Aemulus to “Hold” (from Add) at 32 sen with a lower target price of 30 sen (from 40 sen) and said the company’s 9MFY16 core net loss of RM700,000 was worse than house and consensus’ forecasts due to lower tester equipment sales and higher operating expenses.
AEMULUS Holdings traded moderately above the historical low of 27 sen amid fresh bargain hunting interest. Based on the daily chart, the prevailing trend remains bearish, but the improving technical indicators offer investors a ray of hope it may come out of the rut in the near term. A successful breach of the declining trend line of 37 sen will signal a bullish turnaround, which is likely to see the bulls becoming more aggressive, enroute to the 44 sen-46 sen band.
5 reasons to catch Captain America: Civil War in GSC Maxx, D-BOX, Dolby Atmos and THX
MarketWatch: The March US employment report and other key economic numbers this week could help US. stocks resume their recent winning path as long as that data hit the sweet spot: Not strong enough to add to worries about further interest rate hikes, yet not weak enough to cause concern about a recession. - Reuters Top foreign stories Microsoft meets with private equity over Yahoo deal: Microsoft Corp executives are in early talks with potential Yahoo Inc investors about contributing to financing to buy the troubled Internet company, a person familiar with the situation said.
KUALA LUMPUR, Feb 16 ― The benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) opened higher in the early session today, lifted by fresh buying appetite in heavyweights and external factors including an oil price rebound. At 9.15am, the FBM KLCI was
KUALA LUMPUR (Feb 16): The FBM KLCI extended its gains at mid-morning today in line with the resurgent regional markets. At 10am, the FBM KLCI rose 8.75 points to 1,658.71. The top gainers included Latitude Tree Holdings Bhd, Guinness Anchor Bhd, Genting Bhd, Carlsberg Brewery (M) Holdings Bhd, Axiata Group Bhd, CIMB Group Holdings Bhd, UMW Holdings Bhd, Tek Seng Holdings Bhd, AMMB Holdings Bhd and Sime Darby Bhd.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...